See also this year's filing and all EDGAR filings for this company.
PDF Report 0001208261_2012_Immune_Pharmaceuticals_INC.pdf
Logs
| warning | The stock price does not exist | industry.us_generic | {} |
| warning | Missing logo | subcommand.report | {} |
| info | NetIncome node detected by tax heuristic | input.sec.calculation_linkbase.edgar_model_mapping | {'net_inc_node': 'NetIncomeLossAvailableToCommonStockholdersBasic'} |
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'0020 - Statement - Consolidated Statements of Operations and Comprehensive Loss': 17, '0021 - Statement - Consolidated Statements of Operations and Comprehensive Loss Calc 2': 2}} |
Graph
Absolute values for 0001208261, Immune Pharmaceuticals INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 6,737,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 120,000 |
| 3 | remainder_Assets | 664,000 |
| 4 | LiabilitiesCurrent | 12,237,000 |
| 5 | LiabilitiesNoncurrent | 365,000 |
| 6 | remainder_Liabilities | 12,065,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 6,452,000 |
| 9 | ResearchAndDevelopmentExpense | 7,853,000 |
| 10 | remainder_Expenses | 696,000 |
| 11 | remainder_Revenues | 944,000 |
| 12 | remainder_NetIncome | -1,599,000 |
| 13 | remainder_ComprehensiveNetIncome | 299,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 7,521,000 |
| 1 | Liabilities | 24,667,000 |
| 2 | Expenses | 15,001,000 |
| 3 | Revenues | 944,000 |
| 4 | StockholdersEquity | -17,146,000 |
| 5 | NetIncome | -15,656,000 |
| 6 | ComprehensiveNetIncome | -15,506,500 |
| 7 | BaseVar | 25,015,500 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | -3.29 |
| 9 | EconomicCapitalRatio | 0.595 |
Edgar->Model Mapping
Feature Distribution
